Isn't the main issue not that we're lacking doses (for vulnerable pops), but that we're distributing the doses we do have very slowly? How does this address tha

Isn't the main issue not that we're lacking doses (for vulnerable pops), but that we're distributing the doses we do have very slowly? How does this address that (if it does at all)?